Methanoanthracene compound, pharmaceutical composition containing the same for treating nerve derangement, production of the compound and intermediate

PURPOSE: To provide a new methanoanthracene compound having dopamine antagonist activity in the D 2 receptor and useful for a neuroleptic. CONSTITUTION: The compound of formula I, formula II or formula III (X, Y are each H, a halo, alkoxy; R 2 is (A) an alkyl, phenylalkyl, alkenyl, cycloalkyl, etc., (B) an alkoxyalkyl, alkoxyalkoxy, henyloxaylkyl, etc., (C) an alkylamino, phenylamino, naphthylamino, heterocyclicamino, etc., (D) an alkoxy, cycloalkyloxy, phenylalkoxy, etc.; R 1 is 2-pyrimidinyl or 2-pyridyl; R" is 4- morpholino), for example, N-(1-[(9S,10S)-(+)-2-chloro-9,10-dihydro-9,10- methanoanthracene-9-ylmethyl]-4-piperidyl)-2ethoxy-acetamide. The compound of the formula I which R 2 is group A or B is obtained by allowing an amine of formula IV to react with R 2 COOH of the formura. COPYRIGHT: (C)1993,JPO